Author:
Feliu J, ,Salud A,Escudero P,López-Gómez L,Pericay C,Castañón C,de Tejada M R López,Rodríguez-García J M,Martínez M P,Martín M Sanz,Sánchez J J,Barón M González
Publisher
Springer Science and Business Media LLC
Reference31 articles.
1. Aparicio J, Vicent JM, Maestu I, Garcera S, Busquier I, Bosch C, Llorca C, Díaz R, Fernández-Martos C, Galán A (2003) Multicenter phase II trial evaluating a three-weekly scheduled irinotecan plus raltitrexed in patients with 5-fluorouracil-refractory, advanced colorectal cancer. Ann Oncol 14: 1121–1125
2. Aschele C, Baldo C, Sobrero AF, Debernardis D, Bornmann WG, Bertino JR (1998) Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro. Clin Cancer Res 4: 1323–1330
3. Carnaghi C, Rimassa L, Garassino I, Zucali PA, Masci G, Fallini M, Morenghi E, Santoro A (2002) Irinotecan and raltitrexed: an active combination in advanced colorectal cancer. Ann Oncol 13: 1424–1429
4. Cocconi G, Cunningham D, Van Custem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM (1998) Open, randomized multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. J Clin Oncol 16: 2943–2952
5. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31–41
Cited by
22 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献